SEARCH

SEARCH BY CITATION

References

  • 1
    Godlee F. The Cochrane collaboration. BMJ 1994; 309: 969-970.
  • 2
    Blumberg BS, Gerstley BJ, Hungerford DA, London WT, Sutnick AI. A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis. Ann Intern Med 1967; 66: 924-931.
  • 3
    Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, Kuo G. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321: 1494-1500.
  • 4
    Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007; 132: 1979-1998.
  • 5
    Roseman M, Milette K, Bero LA, Coyne JC, Lexchin J, Turner EH, Thombs BD. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. JAMA 2011; 305: 1008-1017.
  • 6
    DeMets DL, Califf RM. A historical perspective on clinical trials innovation and leadership: where have the academics gone? JAMA 2011; 305: 713-714.
  • 7
    Blümle A, Meerpohl JJ, Rücker G, Antes G, Shumacher M, von Elm E. Reporting of eligibility criteria of randomised trials: cohort study comparing trial protocols with subsequent articles. BMJ 2011; 342: d1828.
  • 8
    Stevens A, Chalkidou K, Littlejohns P. The NHS: assessing new technologies, NICE, and value for money. Clin Med 2011; 11: 247-250.
  • 9
    Llovet JM, Ricci S, Mazzafero V, Hilgard P, Gane A, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
  • 10
    Manns MP, Woynarowski M, Kreisel W, Lurie Y, Rust C, Zuckerman E, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010; 139: 1198-1206.
  • 11
    Pattullo V, McAndrews MP, Damyanovich A, Heathcote EJ. Influence of hepatitis C virus on neurocognitive function in patients free from other risk factors: validation from therapeutic outcomes. Liver Int 2011; 31: 1028-1038.
  • 12
    Krugman S, Giles JP, Hammond J. Infectious hepatitis. Evidence for two distinctive clinical, epidemiological, and Immunological types of infection. JAMA 1967; 200: 365-373.
  • 13
    Miller FG, Joffe S. Equipoise and the dilemma of randomized clinical trials. N Engl J Med 2011; 364: 476-480.
  • 14
    Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-174.
  • 15
    Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. HEPATOLOGY 2009; 50: 1360-1369.
  • 16
    Freedman ND, Curto TM, Lindsay KL, Wright EC, Sinha R, Everhart JE; and the HALT-C Trial Group. Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Gastroenterology 2011; 140: 1961-1969.
  • 17
    Biselli M, Gitto S, Gramonzi A, Di Donato R, Brodosi L, Ravaioli M, et al. Six score systems to evaluate candidates with advanced cirrhosis for orthotopic liver transplant: which is the winner? Liver Transpl 2010; 16: 964-973.
  • 18
    Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971; 40: 159-185.
  • 19
    Feld JJ, Dinh H, Arenovich T, Marcus WA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. HEPATOLOGY 2005; 42: 53-62.
  • 20
    Kuiper EM, Hansen BE, de Vries RA, den Onden-Muller JW, van Ditzhuijsen TJ, Haagsma EB, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009; 136: 1281-1287.
  • 21
    Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. HEPATOLOGY 2009; 50: 808-814.
  • 22
    Sinakos E, Marschall HU, Kowdley KV, Befeler A, Keach J, Lindor K. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: relation to disease progression. HEPATOLOGY 2010; 52: 197-203.
  • 23
    Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350.
  • 24
    Hitomi Y, Cirulli ET, Fellay J, McHutchison JG, Thompson AJ, Gumbs CE, et al. Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. Gastroenterology 2011; 140: 1314-1321.
  • 25
    Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
  • 26
    Mathurin P, O'Grady J, Carithers RL, Phillips M, Louvet A, Mendenhall CL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011; 60: 255-260.
  • 27
    Forrest EH, Morris AJ, Stewart S, Phillips M, Oo YH, Fisher NC, et al. The Glasgow alcoholic hepatitis score identifies patients who may benefit from corticosteroids. Gut 2007; 56: 1743-1746.
  • 28
    Sort P, Navasa M, Arroyo V, Aldequer X, Planas R, Ruiz-de-Arbol L, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403-409.
  • 29
    Fernández J, Navasa M, Planas R, Montuliu S, Monfort D, Soriano G, et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007; 133: 818-824.
  • 30
    de Bruijn KM, Blendis LM, Zilm DH, Carlen PL, Anderson GH. Effect of dietary protein manipulation in subclinical portal-systemic encephalopathy. Gut 1983; 24: 53-60.
  • 31
    Córdoba J, López-Hellín J, Planas M, Sabín P, Sanpedro F, Castro F, et al. Normal protein diet for episodic hepatic encephalopathy: results of a randomized study. J Hepatol 2004; 41: 38-43.
  • 32
    Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010; 362: 1071-1081.
  • 33
    Campbell MS, Bensinger CM, Sanyal AJ, Gennings C, Wong F, Kowdley KV, et al. Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapy. HEPATOLOGY 2005; 42: 635-640.
  • 34
    Lo GH, Chen WC, Wang HM, Lee CC. Controlled trial of ligation plus nadolol versus nadolol alone for the prevention of first variceal bleeding. HEPATOLOGY 2010; 52: 230-237.
  • 35
    García-Pagán JC, Villanueva C, Albillos A, Bañares R, Morillas R, Abraldes JG, Bosch J. Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial. Gut 2009; 58: 1144-1150.
  • 36
    Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850.
  • 37
    Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416.
  • 38
    Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
  • 39
    McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362: 1292-1303.
  • 40
    Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
  • 41
    Zeuzem S, Buggisch P, Agarwal K, Manns M, Marcellin P, Foster GR, et al. Dual, triple, and quadruple combination treatment with ribavirin or PegIFN/RBV for up to 28 days in treatment naïve G1 HCV subjects. Presented at the 61st Annual meeting of the American Association for the Study of Liver Diseases, October 29-November 2, 2010, Boston, MA. LB#1.
  • 42
    Gane EJ, Stedman RA, Hyland RH, Sorensen RD, Symonds WT, Hindes R, et al. Once daily PSI-7977 plus RBV: pegylated interferon alpha not required for complete rapid viral response in treatment-naïve patients with HCV GT2 or GT3. Program and abstracts of The Liver Meeting 2011: American Association for the Study of Liver Diseases (AASLD) 62nd Annual Meeting, November 9-13, 2011, Boston, MA. Abstract #34.
  • 43
    Bruno S, Stroffolini T, Colombo M, Bollani S, Benveqnù L, Mazzella G, et al. Italian Association of the Study of the Liver Disease (AISF). Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. HEPATOLOGY 2007; 45: 579-587.
  • 44
    Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-684.
  • 45
    Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. HEPATOLOGY 2009; 49: 739-744.
  • 46
    Veldt BJ, Chen W, Heathcote EJ, Wedenmeyer H, Reichen J, Hofmann WP, et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. HEPATOLOGY 2008; 47: 1856-1862.
  • 47
    Wang CS, Yao WJ, Chang TT, Wang ST, Chou P. The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses. Cancer Epidemiol Biomarkers Prev 2009; 18: 2054-2060.
  • 48
    Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HL; and the HBV 99-01 Study Group. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006; 101: 297-303.
    Direct Link:
  • 49
    Heathcote EJ, Marcellin P, Buti M, Gane E, de Man RA, Krastev Z, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140: 132-143.
  • 50
    Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. HEPATOLOGY 2011; 53: 763-773.
  • 51
    Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-1010.
  • 52
    Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer N, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-1020.
  • 53
    Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol 2011; 106: 1264-1271.
  • 54
    Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531.
  • 55
    El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750.
  • 56
    Chen TH, Yen MF, Lu SN, Sun CA, Huang GT, et al. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer 2002; 98: 257-261.
  • 57
    Friedman SL, Bansal MB. Reversal of hepatic fibrosis—fact or fantasy? HEPATOLOGY 2006; 43: S82-S88.
  • 58
    Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524-530.
  • 59
    Lee J, Belanger A, Doucette JT, Stanca C, Friedman S, Bach N. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007; 5: 1313-1315.
  • 60
    Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, Lu Y, et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009; 360: 2544-2555.
  • 61
    Melum E, Franke A, Schramm C, Weismüller TJ, Gotthardt DN, Offner FA, et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet 2011; 43: 17-19.
  • 62
    Kwong JC, Crowcroft NS, Campitelli MA, Ratnasingham S, Daneman N, Deeks SL, Manuel DG. Ontario Burden of Infectious Disease Study Advisory Group; Ontario Burden of Infectious Disease Study (ONBOIDS): an OAHPP/ICES Report. Toronto, Ontario, Canada: Ontario Agency for Health Protection and Promotion, Institute for Clinical Evaluative Sciences; 2010.
  • 63
    Sam JJ, Heathcote EJ, Wong DKh, Wooster DL, Shah H. Hepatitis B learning needs assessment of family medicine trainees in Canada: results of a nationwide survey. Can J Gastroenterol 2011; 25: 127-134.
  • 64
    Kanwal F, Schnitzler MS, Bacon BR, Hoang T, Buchana PM, Asch SM. Quality of care in patients with chronic hepatitis C virus infection: a cohort study. Ann Intern Med 2010; 153: 231-239.
  • 65
    Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 1855-1859.
  • 66
    Siddiqui MR, Gay N, Edmunds WJ, Ramsay M. Economic evaluation of infant and adolescent hepatitis B vaccination in the UK. Vaccine 2011; 29: 466-475.